The phrase "average efficacy over" is correct and usable in written English.
It can be used when discussing the effectiveness of a treatment, intervention, or method across a specific period or group.
Example: "The study measured the average efficacy over a six-month period to determine the treatment's long-term benefits."
Alternatives: "mean effectiveness across" or "typical efficacy throughout".
The average efficacy over Seasons 1 and 2 against culture-confirmed influenza illness (CCI), or laboratory-confirmed influenza illness (LCI) were secondary endpoints.
However, the numerically greater benefit on osteitis and synovitis measured by MRI, and the posthoc analysis estimating average efficacy over the 12-month treatment period, are suggestive that abatacept monotherapy may have a greater efficacy benefit compared with MTX.
The primary efficacy analysis was based on the average efficacy over Seasons 1 and 2 and assessed the null hypothesis that the average efficacy in the actively immunized group was ≤ 35%, against the alternative hypothesis that average efficacy was >35%.
The primary endpoint was the average efficacy over Seasons 1 and 2 for the prevention of culture-confirmed influenza illness due to influenza A or B virus strains antigenically matching those in the vaccine (i.e. vaccine-matched, culture-confirmed influenza; VMCCI).
Despite a good degree of 'vaccine-match' among the influenza isolates in the trial (75.5%), and a strong immune response to the vaccine in both years, the average efficacy over Seasons 1 and 2 of TIV against VMCCI was only 46.3%, with a one-sided 97.5% CI lower bound of 9.8%.
Despite a good immune response, and an average efficacy over two influenza seasons against laboratory-confirmed influenza of 63.2%, the pre-specified target (lower one-sided 97.5% confidence bound for efficacy > 35%) for the primary efficacy endpoint, the prevention of VMCCI, was not met.
At the PHO5-HO locus, the two DNA sequences immediately flanking the induced HO cleavage site and represented by amplicons F to I, were captured with an average efficacy of 10.3% over total DNA (before immunoprecipitation) representing a 10-fold enrichment over the amplicons E and J not harboring the HO site (Figure 5b).
This randomized, placebo-controlled trial showed that the average efficacy of TIV for the prevention of VMCCI over the 2005-2006 and 2006-2007 influenza seasons was 46.3%.
The antidepressants described above have comparable average efficacy [ 9].
If a range of efficacies were given or different efficacies given for different disease serotypes, we used the average efficacy.
To be consistent, we increased the first-year efficacy to 90.7% so that the average vaccine efficacy over 2 years would be equal to 87.4%.
